Introduction The lack of feasible therapies and comorbidities aggravate the COVID-19 case–
fatality rate (CFR). However, reports examining CFR associations with diabetes, concomitant …

Background Pharmacological treatments including antivirals (Lopinavir/Ritonavir), Immuno-
modulatory and anti-inflammatory drugs including, Tocilizumab and Hydroxychloroquine …

Introduction Use of hydroxychloroquine in patients with coronavirus disease 2019 (COVID-
19) was widespread and uncontrolled until recently. Patients vulnerable to severe COVID-19 …

ABSTRACT BACKGROUND Currently, there is no proven effective therapy nor vaccine for
the treatment of SARS-CoV-2. Evidence regarding the potential benefit of early …

Background Data from nonrandomized studies have suggested that hydroxychloroquine
could be an effective therapeutic agent against coronavirus disease 2019 (COVID-19) …

Abstract Background The SARS-CoV-2 pandemic has caused over 400,000 deaths
worldwide thus far, and poses therapeutic challenges for millions of patients. There is …

Objective Since the severity of symptoms affects the treatment option for Coronavirus
Disease 2019 (COVID-19) patients, the treatment pattern for mild to moderate non-ICU …

Background In this study, we aimed to compare the intensive care unit (ICU) admission rate
of hospitalized mild/moderate COVID-19 patients treated with hydroxychloroquine (HCQ) …

Objective: Studies have indicated that hydroxychloroquine (HCQ) exerts antiviral effects
against SARS-CoV-2 in vitro. However, trials regarding its effects on patients are very …

Abstract Significance The United States is in an acceleration phase of the COVID-19
pandemic. Currently there is no known effective therapy or vaccine for treatment of SARS …